Navigation Links
Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
Date:5/30/2012

SAN FRANCISCO, May 30, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2012 Global Healthcare Conference at The Grand Hyatt New York on Tuesday, June 5, 2012 at 11:30 a.m. Eastern Time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until July 5, 2012.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, has completed Phase 1 development and is being prepared for a Phase 2 study.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharm
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, ... interactive music products, today announced that it has ... leading manufacturer and supplier of innovative prosthetic, orthotic ... As part of the agreement, RSL Steeper will ... solution specifically configured for use within UK residential ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) has ... (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena Cava ... by 2016. The North America ... while Europe claims approximately 27% ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
... Grifols, a global healthcare company and biopharmaceutical manufacturer based ... an Expert Advisory Council in Transfusion Medicine drawing on ... across the globe.  The role of the Expert Advisory ... Grifols, own transfusion medicine research and development activities. ...
... CareFusion Corporation (NYSE: CFN ... of Carlos M. Nunez, M.D. as its chief medical officer ... and hospitalist as well as an experienced health care technology ... the areas of clinical effectiveness, information technology, public policy and ...
Cached Medicine Technology:Grifols Establishes Expert Advisory Council in Transfusion Medicine 2Grifols Establishes Expert Advisory Council in Transfusion Medicine 3CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... , , ABBOTT PARK, Ill., ... goal of a 5 percent reduction in the amount of packaging ... effort to minimize its impact on the environment. To achieve ... of launching, more than 40 sustainable packaging initiatives across its nutrition, ...
... to alleviate the shortage of available liver donors. Accurate estimation ... and recipient is crucial. Scholars of different countries established several ... most accurate for Chinese adults has remained unclear. ... on August 28, 2009 in the World Journal of ...
... type of cellular adaptor protein and transcriptional co-activator. In ... overexpressed and highly activated in hepatic cancers and mammary ... of the inhibitor of apoptotic protein (IAP) family, which ... cell protease receptor-1 in the human genomic library in ...
... Antidepressant drug Paxil, which generated about 2.1% of GlaxoSmithKline,s ... defects, but the world,s second-biggest drugmaker hid its risks to ... , According to available information, Glaxo failed ... Paxil,s risks. The Philadelphia trial is the first of more ...
... Md., Sept. 16 On September 15, 2009, GenVec, Inc. (Nasdaq: ... Market stating that the minimum bid price of the Company,s common ... and that the Company was therefore not in compliance with Marketplace ... on the listing of the Company,s common stock on The NASDAQ ...
... , WEDNESDAY, Sept. 16 (HealthDay News) -- Scientists have long ... But now researchers have found a possible equalizer -- a ... youngest poor kids may be enough to offset negative ... skills, at least up to the fifth grade, according to ...
Cached Medicine News:Health News:Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 2Health News:Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 3Health News:Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 4Health News:Glaxo Official Memo Urged Scientists to Withhold Information About Paxil's Risks, Trial Hears; Pharmaceutical Industry Today Offers Complete News Coverage 2Health News:GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance 2Health News:GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance 3Health News:Better Day Care, Smarter Kids? 2Health News:Better Day Care, Smarter Kids? 3Health News:Better Day Care, Smarter Kids? 4
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis....
Medicine Products: